Sagimet Biosciences Inc.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
SGMT$10.83+9.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except for share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · As of | ||||||
| · · December 31, · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Assets | | | | | | |
| Current assets: · · · · | ||||||
| Cash and cash equivalents | | $35,021 | | $75,840 | ||
| Short-term marketable securities | | 78,103 | | 75,410 | ||
| Prepaid expenses and other current assets | | | 3,280 | | | 1,524 |
| Total current assets | | | 116,404 | | | 152,774 |
| Long-term marketable securities | | | — | | | 7,408 |
| Operating lease right-of-use assets | | | 78 | | | 77 |
| Total assets | | $116,482 | | $160,259 | ||
| Liabilities and stockholders’ equity | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $1,309 | | $1,425 | ||
| Accrued expenses and other current liabilities | | 3,714 | | 2,951 | ||
| Operating lease liabilities | | 78 | | 78 | ||
| Total current liabilities | | 5,101 | | 4,454 | ||
| Commitments and contingencies (Note 6) | | | | | ||
| Stockholders’ equity: | | | | | ||
| Undesignated preferred stock, $0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | | | — | | | — |
| Series A common stock, $0.0001 per share: 500,000,000 shares authorized; 31,954,105 shares issued and outstanding at December 31, 2025; 30,674,855 shares issued and outstanding at December 31, 2024 | | | 3 | | | 3 |
| Series B common stock, $0.0001 per share: 15,000,000 shares authorized; 567,494 shares issued and outstanding at December 31, 2025; 1,520,490 shares issued and outstanding at December 31, 2024 | | | — | | | — |
| Additional paid-in capital | | 457,607 | | 450,883 | ||
| Accumulated deficit | | (346,349) | | (295,311) | ||
| Accumulated other comprehensive income | | 120 | | 230 | ||
| Total stockholders’ equity | | | 111,381 | | 155,805 | |
| Total liabilities and stockholders’ equity | | $116,482 | | $160,259 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.